|
|
|
International Clinical Trials
|
As life expectancy rises and clinical investigations and treatments get ever more effective and complex, expectations of what health systems should deliver in terms of keeping people healthy for longer are, rightly, growing. However, the longstanding challenges of wide variation in access and quality, even within a single system, and spiralling costs are putting an ever greater strain on health systems and pose a risk to continued progress.
Today, healthcare quality is mainly understood in terms of process measures, such as waiting times, length of stay, and discharge rates as well as the unintended consequences or complications of care, such as hospital acquired infections and mortality. These measures are clearly important and need to be measured and managed, but they do not help patients or clinicians understand the actual results of care from the perspective of the patient. This includes information about which patients get better or worse or in what circumstances treatment is successful, whether it is generally done at the right time by a particular doctor or hospital and, if not, why not, how long the benefits last or the relative successes between treatments, doctors, and hospitals. The International Consortium of Health Outcomes Measurement (ICHOM) define ‘outcomes’ as: “The results people care about most when seeking treatment, including functional improvement and the ability to live normal, productive lives” (1). ICHOM was established in 2014 as a partnership between Harvard Business School, Boston Consulting Group, and the Karolinska Institutet in Sweden to set a global standard for outcomes measurement at the level of the clinical condition.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
As life expectancy rises and clinical investigations and treatments get
ever more effective and complex, expectations of what health systems
should deliver in terms of keeping people healthy for longer are,
rightly, growing. However, the longstanding challenges of wide variation
in access and quality, even within a single system, and spiralling
costs are putting an ever greater strain on health systems and pose a
risk to continued progress.
Today, healthcare quality is mainly
understood in terms of process measures, such as waiting times, length
of stay, and discharge rates as well as the unintended consequences or
complications of care, such as hospital acquired infections and
mortality. These measures are clearly important and need to be measured
and managed, but they do not help patients or clinicians understand the
actual results of care from the perspective of the patient. This
includes information about which patients get better or worse or in what
circumstances treatment is successful, whether it is generally done at
the right time by a particular doctor or hospital and, if not, why not,
how long the benefits last or the relative successes between treatments,
doctors, and hospitals. The International Consortium of Health Outcomes
Measurement (ICHOM) define ‘outcomes’ as: “The results people care
about most when seeking treatment, including functional improvement and
the ability to live normal, productive lives” (1). ICHOM was established
in 2014 as a partnership between Harvard Business School, Boston
Consulting Group, and the Karolinska Institutet in Sweden to set a
global standard for outcomes measurement at the level of the clinical
condition.
|
|
|
|
|
|
 |
News and Press Releases |
 |
Aptus Clinical enters into a global partnership agreement with Artelo Biosciences
We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >> |
|
 |
White Papers |
 |
|
Key to Outsourcing Method Development and Validation: A Pragmatic Approach
RSSL
In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP).
Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >> |
|
 |
Industry Events |
 |
6th Annual Single Cell Analysis Congress
8-9 November 2018, London, UK
Oxford
Global is proud to present its 6th Annual Single Cell Analysis Congress taking
place on 8-9 November 2018 in London. Part of the Genomics
& Synthetic Biology Series UK, the congress will bring together over 600
end users representing internationally renowned research & academic
institutions, clinical research institutions, healthcare organisations as well
as leading pharmaceutical and biotech companies.
More info >> |
|
|
